The FDA permitted marketing of first game-based digital therapeutic to improve attention function in children with ADHD
Biotechnology, Diagnostics, Disease, FDA, Life Science News, Medical Device, Neurology, Therapeutics
On Jun. 15, 2020, the U.S. Food and Drug Administration (FDA) permitted marketing of the first game-based digital therapeutic device to improve attention function in children with attention deficit hyperactivity disorder (ADHD).
The prescription-only game-based device, called EndeavorRx, is indicated for pediatric patients ages 8 to12 years old with primarily inattentive or combined-type ADHD who have demonstrated an attention issue.
Tags:
Source: U.S. Food and Drug Administration
Credit:
